The endogenous thrombin potential in patients with left ventricular assist device or heart transplant.
Heartmate
bleeding
coagulation
left ventricular assist device
thrombin generation
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
01
2023
accepted:
23
03
2023
medline:
1
5
2023
pubmed:
1
5
2023
entrez:
1
5
2023
Statut:
epublish
Résumé
The Heartmate 3 (HM 3) is a left ventricular assist device featuring less shear stress, milder acquired von Willebrand syndrome, and fewer bleeding incidences than its predecessor the Heartmate II (HM II). The novel surface coating of the HM 3 suggests less contact activation of plasmatic coagulation. We hypothesized that patients with HM 3 exhibit fewer aberrations in their thrombin potential than patients with HM II. We compared these results with the thrombin potential of patients with heart transplantation (HTX). Thrombin generation in plasma samples of patients with HM II ( Three days postoperatively HM II patients exhibited a lower endogenous thrombin potential (ETP) than HM 3 and HTX patients (HM II: 947 ± 291 nM*min; HM 3: 1231 ± 176 nM*min; HTX: 1376 ± 162 nM*min, We observed a more aberrant thrombin generation in HM II than in HM 3 despite comparable anticoagulation and routine parameters. A trend toward lower values was still observable in HM 3 compared to HTX patients. Calibrated automated thrombography may be a good tool to monitor the coagulation state of these patients and guide anticoagulation in the future.
Sections du résumé
Background
UNASSIGNED
The Heartmate 3 (HM 3) is a left ventricular assist device featuring less shear stress, milder acquired von Willebrand syndrome, and fewer bleeding incidences than its predecessor the Heartmate II (HM II). The novel surface coating of the HM 3 suggests less contact activation of plasmatic coagulation. We hypothesized that patients with HM 3 exhibit fewer aberrations in their thrombin potential than patients with HM II. We compared these results with the thrombin potential of patients with heart transplantation (HTX).
Methods
UNASSIGNED
Thrombin generation in plasma samples of patients with HM II (
Results
UNASSIGNED
Three days postoperatively HM II patients exhibited a lower endogenous thrombin potential (ETP) than HM 3 and HTX patients (HM II: 947 ± 291 nM*min; HM 3: 1231 ± 176 nM*min; HTX: 1376 ± 162 nM*min,
Conclusion
UNASSIGNED
We observed a more aberrant thrombin generation in HM II than in HM 3 despite comparable anticoagulation and routine parameters. A trend toward lower values was still observable in HM 3 compared to HTX patients. Calibrated automated thrombography may be a good tool to monitor the coagulation state of these patients and guide anticoagulation in the future.
Identifiants
pubmed: 37122335
doi: 10.3389/fmed.2023.1155496
pmc: PMC10130672
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1155496Informations de copyright
Copyright © 2023 Schlagenhauf, Haidl, Trummer, Berchtold-Herz, Pooth, Strini, Geisen, Beyersdorf and Zieger.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Cardiothorac Surg. 2004 Jun;25(6):971-7
pubmed: 15144997
ASAIO J. 2016 Jul-Aug;62(4):375-83
pubmed: 27195742
Sci Rep. 2019 May 29;9(1):8014
pubmed: 31142810
Blood. 2011 Jun 23;117(25):6777-85
pubmed: 21540459
Front Med (Lausanne). 2022 Feb 25;9:760816
pubmed: 35280873
Eur J Cardiothorac Surg. 2008 Apr;33(4):679-84
pubmed: 18282712
Curr Opin Hematol. 2016 Sep;23(5):445-52
pubmed: 27380557
J Heart Lung Transplant. 2018 Aug;37(8):985-991
pubmed: 29650295
Circulation. 2012 Jun 19;125(24):3038-47
pubmed: 22711669
J Thorac Cardiovasc Surg. 2011 Nov;142(5):1019-26
pubmed: 21397258
Circulation. 1994 Nov;90(5 Pt 2):II87-91
pubmed: 7955291
J Thromb Haemost. 2003 Jul;1(7):1504-14
pubmed: 12871286
Pathophysiol Haemost Thromb. 2003;33(1):4-15
pubmed: 12853707
J Am Heart Assoc. 2018 Jan 13;7(2):
pubmed: 29331958
ASAIO J. 2019 Sep/Oct;65(7):e72-e74
pubmed: 30681438
Eur J Cardiothorac Surg. 2016 Aug;50(2):275-80
pubmed: 26984978
Eur J Cardiothorac Surg. 2019 Jun 1;55(Suppl 1):i31-i37
pubmed: 30608535
J Thromb Haemost. 2015 Oct;13(10):1757-67
pubmed: 26302994
Thromb Haemost. 2010 May;103(5):962-7
pubmed: 20352153
Ann Thorac Surg. 2011 Mar;91(3):740-7; discussion 747-9
pubmed: 21352991
Eur Heart J. 2005 May;26(10):1031-8
pubmed: 15800020
Circ J. 2018 Apr 25;82(5):1309-1318
pubmed: 29237991
Eur J Cardiothorac Surg. 2009 Sep;36(3):580-4
pubmed: 19464915
Thromb Haemost. 2016 Aug 30;116(3):442-51
pubmed: 27121983
Ann Thorac Surg. 2009 Oct;88(4):1171-9
pubmed: 19766802
Ann Thorac Surg. 2011 Nov;92(5):1593-9; discussion 1599-600
pubmed: 22051256